Metabolic Stability and Comprehensive Metabolite Profiling of Chrysotobibenzyl in Human Liver Microsomes and Hepatocytes Employing UPLC‐MS/MS and UPLC‐Orbitrap‐HRMS Analysis
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.70217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Xuanwei Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou University of Chinese Medicine, Guangzhou, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Hepatocytes, Microsomes, Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Chrysotobibenzyl, a bioactive ingredient from Dendrobium chrysotoxum , exhibits potent anti‐tumor activity. However, its metabolic profiles remain unelucidated. This study aimed to disclose the metabolic fates of chrysotobibenzyl using human liver fractions. In vitro metabolism of chrysotobibenzyl was assessed using human liver microsomes and hepatocytes. The concentration of unchanged parent compound was quantified using a validated UPLC‐MS/MS method. Metabolite profiling was achieved by Q‐Exactive Orbitrap HRMS combined with Compound Discoverer software using a mass defect filtering approach, with structures characterized by accurate mass measurement and fragmentation pattern interpretation. Chrysotobibenzyl exhibited poor metabolic stability in human liver microsomes ( t 1/2 : 16.24 min) and hepatocytes ( t 1/2 : 44.35 min). Totally, 36 metabolites were identified, comprising 19 phase I metabolites, 10 glucuronide conjugates, and seven GSH adducts. Using reference standards, M22, M25, M27, and M28 were unambiguously identified as moscatilin, chrysotoxine, erianin, and crepidatin, respectively. The detection of GSH conjugates indicated the formation of reactive metabolites, including ortho ‐quinone and quinone‐methide intermediates. This study demonstrates the effectiveness of UPLC‐MS/MS and UPLC‐Orbitrap‐HRMS platforms for metabolic profiling. Metabolic pathways include demethylation, hydroxylation, dehydrogenation, glucuronidation, and GSH conjugation. These findings provide critical insights into the metabolism of chrysotobibenzyl in humans, enhancing our understanding of its biological activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guangzhou University of Chinese Medicine, Guangzhou, China.
- Department of Rehabilitation, Nan'ao People's Hospital, Shenzhen, China.
- Acupuncture and Moxibustion Department, Luohu District Hospital of Traditional Chinese Medicine, Shenzhen, China.
ORCID-Profile: Lihua Tan
Zitieren
APA
Liu, X., Ge, J., Zhao, N., Liang, Y., Liu, Y., Wang, X., & Tan, L. (2025). Metabolic Stability and Comprehensive Metabolite Profiling of Chrysotobibenzyl in Human Liver Microsomes and Hepatocytes Employing UPLC‐MS/MS and UPLC‐Orbitrap‐HRMS Analysis. Biomedical Chromatography. https://doi.org/10.1002/bmc.70217
Vancouver
Liu X, Ge J, Zhao N, Liang Y, Liu Y, Wang X, et al. Metabolic Stability and Comprehensive Metabolite Profiling of Chrysotobibenzyl in Human Liver Microsomes and Hepatocytes Employing UPLC‐MS/MS and UPLC‐Orbitrap‐HRMS Analysis. Biomedical Chromatography. 2025. doi:10.1002/bmc.70217
BibTeX
@article{Liu2025,
author = {Liu, Xuanwei and Ge, Junsheng and Zhao, Nana and Liang, Yeji and Liu, Yu and Wang, Xiaoman and Tan, Lihua},
title = {Metabolic Stability and Comprehensive Metabolite Profiling of Chrysotobibenzyl in Human Liver Microsomes and Hepatocytes Employing UPLC‐MS/MS and UPLC‐Orbitrap‐HRMS Analysis},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.70217}
}
EUVIMED